Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Acute and chronic leukemias and other life-threatening cancers will now be recognized as presumptive conditions for ...